SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Discussion is focused on reports that Subsquid CEO Wanja Oberhof was charged over alleged fraud at a former company, raising questions about Subsquids governance, ownership, and Rezolves call-option rights. Some traders view the matter as a risk, while others stress that the allegations concern his prior business, not SQD, and do not automatically change Rezolves contractual rights.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FETs recent rebound and perceived relative strength are drawing attention, with bullish traders linking the move to renewed interest in AI tokens and Fetchs AI-agent ecosystem. Others remain cautious, pointing to resistance levels and the tokens sensitivity to Bitcoin and broader crypto-market moves.

WorldFinancial

WLFI is being discussed around World Liberty Financials preliminary conditional OCC approval for a national trust bank tied to its USD1 stablecoin, which bullish traders view as a potential source of utility. Skeptics counter that the token has lagged and raise concerns about Trump-family monetization, while traders disagree over whether the bank development can change its prospects.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention after a sharp rebound, with traders linking renewed interest to Starknets privacy and Bitcoin DeFi efforts, including strkBTC and STRK20, alongside its post-quantum security narrative. Supporters see differentiated infrastructure and growing ecosystem activity, while skeptics remain concerned about token unlocks, dilution and whether the rally can hold.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Traders are focused on the Iran-related oil and refining disruptions driving up jet-fuel costs, which they fear will squeeze American Airlines margins and could prompt further capacity or earnings guidance cuts. Some see scope for a recovery if conflict eases and fuel prices fall, while others point to AALs debt burden and limited fuel protection as reasons for caution.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

A rebound in South Korean equities, linked in traders discussion to strength in AI-related memory and chip stocks such as Samsung and SK Hynix, is drawing attention to KORU. Traders are split between riding the chip-led gains and cautioning that the funds three-times leverage magnifies sharp swings and can deepen losses during selloffs.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Traders are betting on a COMP breakout, pointing to its capped token supply and Compounds institutional push and planned V4 as reasons for potential renewed interest. Optimism about accumulation and technical momentum is countered by frustration over weak price action and concerns about competition and protocol security.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is drawing attention ahead of its Q3 report, with traders weighing whether resilient travel demand and pricing can offset elevated jet-fuel costs; bullish earnings expectations contrast with concerns about fuel pressure and the outlook. Separately, criticism of Deltas choice of Amazon Leo over Starlink and Elon Musks public feud with CEO Ed Bastian are fueling debate about customer experience and competitive positioning.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Uncertainty over DefenCath reimbursement after the TDAPA transition and the level of future CMS payments is driving debate, despite the DaVita contract and reported adoption across major dialysis providers. Bulls point to commercial growth, real-world evidence and possible Medicare Advantage coverage, while skeptics worry about lower revenue and margins; Rezzayos positive Phase 3 results and anticipated filing are additional catalysts drawing attention.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as Irans conditions for reopening the Strait of Hormuz keep oil-supply risks in focus, alongside discussion of OPEC+ holding production quotas steady. Traders are split between those expecting continued support from supply disruption and those pointing to crudes pullback and the possibility of diplomatic progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Bellus Health Inc

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

BLU Bellus Health Inc